UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) March 29, 2007
---------------------------
Interleukin Genetics, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-23413 94-3123681
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
135 Beaver Street Waltham, MA 02452
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(781) 398-0700
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Definitive Material Agreement.
On March 29, 2007, Interleukin Genetics, Inc. has entered into a new
research agreement with Access Business Group International LLC (ABG), a
subsidiary of Alticor Inc. The research agreement encompasses the development of
genetic tests to guide consumers' selection of appropriate skin care products;
the further development of tests for weight management and the risk of
osteoporosis, as well as the development of other tests. Under the terms of the
agreement, Interleukin is eligible to receive up to $2.3 million in additional
research funding during 2007.
A copy of the press release is attached hereto as Exhibit 99.1, and is
incorporated in this Item 1.01 by reference.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press Release dated March 30, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Interleukin Genetics, Inc.
--------------------------
(Registrant)
Date: March 30, 2007 /s/ TIMOTHY J. RICHERSON
--------------------------------
Timothy J. Richerson
Chief Executive Officer
(Signature)